XenTech is a spin-off of Institut Curie, France’s largest cancer research institute, where our scientists have published reference articles since 1989, providing the world’s first proof of concept for the development and use of PDXs.

With over 2500 studies carried out with industrial and academic partners, XenTech’s staff has a comprehensive knowledge of PDX based experimental pharmacology.

Our team ensures high quality research and ethical standards and is continuously working to keep up-to-date with new technologies.